|
1
|
McMurray JJ and Pfeffer MA: Heart failure.
Lancet. 365:1877–1889. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: The task force for
the diagnosis and treatment of acute and chronic heart failure of
the European society of cardiology (ESC)Developed with the special
contribution of the heart Failure Association (HFA) of the ESC. Eur
Heart J. 37:2129–2200. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ishihara S, Kawakami R, Nogi M, Hirai k,
Hashimoto Y, Nakada Y, Nakagawa H, Ueda T, Nishida T, Onoue K, et
al: Incidence and clinical significance of 30-day and 90-day
rehospitalization for heart failure among patients with acute
decompensated heart failure in Japan-From the NARA-HF Study. Circ
J. 84:194–202. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Aimo A, Januzzi JL Jr, Bayes-Genis A,
Vergaro G, Sciarrone P, Passino C and Emdin M: Clinical and
prognostic significance of sST2 in heart failure: JACC review topic
of the week. J Am Coll Cardiol. 74:2193–2203. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Feusette P, Gierlotka M, Tukiendorf A,
Płonka J, Bugajski J, Łabuz-Roszak B and Bryk R: Heart failure in
opole voivodeship-epidemiology and future perspectives. Wiad Lek.
72:112–119. 2019.PubMed/NCBI(In Polish).
|
|
6
|
Jia Q, Wang L, Zhang X, Ding Y, Li H, Yang
Y, Zhang A, Li Y, Lv S and Zhang J: Prevention and treatment of
chronic heart failure through traditional Chinese medicine: Role of
the gut microbiota. Pharmacol Res. 151(104552)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang J, Wu C, Gao L, Du G and Qin X:
Astragaloside IV derived from Astragalus membranaceus: A research
review on the pharmacological effects. Adv Pharmacol. 87:89–112.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Swatek KN and Komander D: Ubiquitin
modifications. Cell Res. 26:399–422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Han ZJ, Feng YH, Gu BH, Li YM and Chen H:
The post-translational modification, SUMOylation, and cancer
(Review). Int J Oncol. 52:1081–1094. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kunz K, Piller T and Müller S:
SUMO-specific proteases and isopeptidases of the SENP family at a
glance. J Cell Sci. 131(jcs211904)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cai R, Gu J, Sun H, Liu X, Mei W, Qi Y,
Xue S, Ren S, Rabinowitz JE, Wang Y, et al: Induction of SENP1 in
myocardium contributes to abnormities of mitochondria and
cardiomyopathy. J Mol Cell Cardiol. 79:115–122. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chhunchha B, Kubo E, Singh P and Singh DP:
Sumoylation-deficient Prdx6 repairs aberrant Sumoylation-mediated
Sp1 dysregulation-dependent Prdx6 repression and cell injury in
aging and oxidative stress. Aging (Albany NY). 10:2284–2315.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bozkurt B: What is new in heart failure
management in 2017? Update on ACC/AHA heart failure guidelines.
Curr Cardiol Rep. 20(39)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kerpen K, Koutrolou-Sotiropoulou P, Zhu C,
Yang J, Lyon JA, Lima FV and Stergiopoulos K: Disparities in death
rates in women with peripartum cardiomyopathy between advanced and
developing countries: A systematic review and meta-analysis. Arch
Cardiovasc Dis. 112:187–198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Frangogiannis NG: The extracellular matrix
in ischemic and nonischemic heart failure. Circul Res. 125:117–146.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang Y, Wu J, Guo S, Lin W, Zhang B, Chen
X, Mo H and Zhan T: The clinical efficacy and safety of the Chinese
herbal medicine Astragalus (Huangqi) preparation for the treatment
of acute myocardial infarction: A systematic review of randomized
controlled trials. Medicine. 98(e15256)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dai H, Jia G, Lu M, Liang C, Wang Y and
Wang H: Astragaloside IV inhibits isoprenaline-induced cardiac
fibrosis by targeting the reactive oxygen species/mitogen-activated
protein kinase signaling axis. Mol Med Rep. 15:1765–1770.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yuan LB, Hua CY, Gao S, Yin YL, Dai M,
Meng HY, Li PP, Yang ZX and Hu QH: Astragalus Polysaccharides
attenuate monocrotaline-induced pulmonary arterial hypertension in
rats. Am J Chin Med. 45:773–789. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
van der Pol A, van Gilst WH, Voors AA and
van der Meer P: Treating oxidative stress in heart failure: Past,
present and future. Eur J Heart Failure. 21:425–435.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Song Z, Wei D, Chen Y, Chen L, Bian Y,
Shen Y, Chen J and Pan Y: Association of astragaloside IV-inhibited
autophagy and mineralization in vascular smooth muscle cells with
lncRNA H19 and DUSP5-mediated ERK signaling. Toxicol Appl
Pharmacol. 364:45–54. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yang P, Zhou Y, Xia Q, Yao L and Chang X:
Astragaloside IV regulates the PI3K/Akt/HO-1 signaling pathway and
inhibits H9c2 cardiomyocyte injury induced by
hypoxia-reoxygenation. Biol Pharm Bull. 42:721–727. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Du FL, Dong WB, Zhang C, Li QP, Kang L,
Lei XP, Guo L and Zhai XS: Budesonide and poractant alfa prevent
bronchopulmonary dysplasia via triggering SIRT1 signaling pathway.
Eur Rev Med Pharmacol Sci. 23:11032–11042. 2019.PubMed/NCBI View Article : Google Scholar
|
